<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649840</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_COVID19_Immunity</org_study_id>
    <nct_id>NCT04649840</nct_id>
  </id_info>
  <brief_title>Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients</brief_title>
  <official_title>Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Republican Research and Practical Center for Epidemiology and Microbiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project: to study the dynamics of the humoral and cellular immunity in&#xD;
      patients after pneumonia caused by the SARS-CoV-2 virus at different time intervals, in order&#xD;
      to predict the duration of immune protection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  to form study groups of patients (at least 60 patients in total) who have recovered from&#xD;
           pneumonia of varying severity caused by the SARS-CoV-2 virus (at least 30 patients in&#xD;
           each of the groups of patients who have had pneumonia in moderate and severe forms);&#xD;
&#xD;
        -  to investigate the parameters of cellular immunity (the content of antigen-specific&#xD;
           T-cells to the main viral antigens - proteins S, N, M) in patients of different groups&#xD;
           included in the trials, in dynamics 3, 6, 9 and 12 months after the COVID-19-associated&#xD;
           pneumonia;&#xD;
&#xD;
        -  to investigate the indicators of humoral immunity (the content of IgG to the main viral&#xD;
           antigens - proteins S, N, M) in patients of different groups included in the trials, in&#xD;
           dynamics 3, 6, 9 and 12 months after the COVID-19-associated pneumonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The dynamics of humoral and cellular immunity</measure>
    <time_frame>1 year</time_frame>
    <description>The dynamics of both humoral and cellular immunity in response to COVID-19 infection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID-19 moderate</arm_group_label>
    <description>moderate COVID-19 associated pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 severe</arm_group_label>
    <description>severe COVID-19 associated pneumonia</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Humoral and cellular immunity</intervention_name>
    <description>Humoral (IgG) and cellular (antigen-specific cells) immunity</description>
    <arm_group_label>COVID-19 moderate</arm_group_label>
    <arm_group_label>COVID-19 severe</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients recovered from the COVID-19 associated pneumonia (moderate and severe)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients recovered from the COVID-19 associated pneumonia (moderate and severe) in 1-3&#xD;
             month interval before inclusion into the trial;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cancer;&#xD;
&#xD;
          -  drug and alcohol addiction;&#xD;
&#xD;
          -  autoimmune diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Hancharou, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

